56 completed, 13 recruiting, 5 terminated, 4 active not recruiting. 32 Phase 3, 26 Phase 2, 22 Phase 1, 3 Phase 4, 1 Early Phase 1.
Follow Vanda Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use Tradipitant, Placebo - Nausea and Vomiting, Obesity | Phase 3 | Recruiting | Vanda Pharmaceuticals | 280 | 2026-03-27 | 2026-04-20 |
| Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Ponesimod - Moderate-to-severe Chronic Plaque Psoriasis | Phase 3 | Recruiting | Vanda Pharmaceuticals | 300 | 2026-02-17 | 2026-09-22 |
| An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye VSJ-110, Placebo - Dry Eye | Phase 2 | Recruiting | Vanda Pharmaceuticals | 160 | 2025-10-01 | 2025-09-17 |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder VQW-765, Placebo - Social Anxiety Disorder (SAD) | Phase 3 | Active not recruiting | Vanda Pharmaceuticals | 500 | 2025-09-22 | 2026-08-17 |
| Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension iloperidone, Placebo - Hypertension, Uncontrolled Hypertension | Phase 2 | Recruiting | Vanda Pharmaceuticals | 240 | 2025-09-15 | 2026-02-27 |
| Randomized Withdrawal Study in Patients With Schizophrenia iloperidone, placebo - Schizophrenia | Phase 3 | Recruiting | Vanda Pharmaceuticals | 400 | 2025-05-14 | 2026-01-12 |
| Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient VCA-894A - Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD) | Phase 1 / Phase 2 | Active not recruiting | Vanda Pharmaceuticals | 1 | 2025-05-13 | 2026-08-19 |
| Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Trichostatin A - Onychomycosis of Toenail | Phase 2 | Active not recruiting | Vanda Pharmaceuticals | 50 | 2025-05-05 | 2026-02-04 |
| Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Tasimelteon Oral Suspension, Placebo - Insomnia Disorder | Phase 3 | Recruiting | Vanda Pharmaceuticals | 420 | 2025-04-21 | 2026-06-05 |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Milsaperidone, Placebo - Major Depressive Disorder (MDD) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 500 | 2025-03-03 | 2026-09-24 |
| A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use Tradipitant, Placebo - Obesity | Phase 2 | Completed | Vanda Pharmaceuticals | 124 | 2025-02-25 | 2025-11-12 |
| Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant Tasimelteon, Placebo - Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm | Phase 3 | Recruiting | Vanda Pharmaceuticals | 60 | 2024-10-08 | 2024-11-22 |
| Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions VHX-896 and iloperidone, Iloperidone and VHX-896 - Schizophrenia, Bipolar I Disorder | Phase 1 | Completed | Vanda Pharmaceuticals | 26 | 2024-07-11 | 2025-09-19 |
| A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye VSJ-110, Placebo - Dry Eye | Phase 2 | Unknown | Vanda Pharmaceuticals | 40 | 2024-02-29 | 2024-03-06 |
| Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Tradipitant - Idiopathic Gastroparesis, Diabetic Gastroparesis | Phase 3 | Completed | Vanda Pharmaceuticals | 17 | 2024-01-09 | 2026-10-19 |
| The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD) Tasimelteon - REM Behavior Disorder | Early Phase 1 | Terminated | Brigham and Women's Hospital | 20 | 2023-09-30 | 2025-10-09 |
| Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness Tradipitant, Placebo - Motion Sickness | Phase 3 | Completed | Vanda Pharmaceuticals | 316 | 2023-09-09 | 2025-04-04 |
| Safety and Tolerability of Open-Labeled Iloperidone in Adolescents Iloperidone - Schizophrenia, Bipolar I Disorder | Phase 4 | Recruiting | Vanda Pharmaceuticals | 100 | 2023-05-24 | 2026-10-01 |
| Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Tradipitant - Motion Sickness | Phase 3 | Active not recruiting | Vanda Pharmaceuticals | 705 | 2023-02-27 | 2026-04-16 |
Showing 20 of 85. Sign in to see all of them.
Schizophrenia (9) · Sleep Disorders, Circadian Rhythm (9) · Sleep Wake Disorders (7) · Chronobiology Disorders (6) · Blindness (5) · Nausea (5) · Nervous System Diseases (5) · Psoriasis (5) · Vomiting (5) · Dermatitis, Atopic (4) · Dyssomnias (4) · Eye Diseases (4) · Gastroparesis (4) · Motion Sickness (4) · Eczema (3)
tasimelteon (22) · iloperidone (14) · LY686017 (4) · Midazolam (2) · ponesimod (2) · trichostatin A (2) · Data Collection (1) · Double-Blind Method (1) · Ethanol (1) · Fluvoxamine (1) · Ketoconazole (1) · Rifampin (1) · Rosiglitazone (1) · Spermine Synthase (1) · Standard of Care (1)
United States (75) · Poland (10) · Germany (8) · Canada (5) · France (4) · Georgia (4) · South Korea (3) · Turkey (Türkiye) (3) · Australia (2) · Bulgaria (2) · Czechia (2) · India (2) · Malaysia (2) · Morocco (2) · Romania (2)
Milko Radicioni, MD (2) · Charles Bowden, MD (1) · Gunther Birznieks (1) · Marlene Dressman, PhD (1) · Milena Pavlova, M.D. (1)
PMID 19054552, PMID 26466871, PMID 42047557, PMID 42150111, PMID 19573479, PMID 27379654, PMID 32693185, PMID 32754110, PMID 34353696, PMID 35644931, PMID 38033548, PMID 38236020, PMID 38237696, PMID 40103934, PMID 40758573
2017 (2)